All news

Wells Fargo starts Korsana Biosciences at overweight, $44 target

Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash

Wells Fargo initiated coverage on Korsana Biosciences (NASDAQ: KRSA) with an overweight rating and a $44 price target, implying roughly 41% upside. The biotech's lead asset, KRSA-028, targets Alzheimer's Disease using a transferrin receptor shuttle to improve drug delivery and amyloid beta clearance. UBS, Stifel, TD Cowen and Wedbush also issued positive ratings.

Read original source

KRSA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.